Summary
Dr. Chapa reviews the latest evidence on low-dose aspirin therapy in pregnancy, focusing on an upcoming clinical opinion in the American Journal of OBGYN. The episode traces the evolution of aspirin dosing guidelines from ACOG's initial 2013 recommendation through the 2018 expanded risk algorithm. The key debate centers on whether 81 mg is sufficient or if higher doses of 150-162 mg provide better preeclampsia prevention. The episode covers multiple meta-analyses and randomized trials showing a dose-response relationship, with doses above 100 mg providing superior preeclampsia risk reduction. Chapa also discusses emerging data on aspirin's potential to reduce preterm birth and the controversy around universal versus risk-factor-based prescribing. The timing of initiation (before 16 weeks) and the safety profile of higher doses are addressed using current evidence.
Key Points
- ACOG currently recommends 81 mg aspirin for preeclampsia prevention, but growing evidence supports moving to 150-162 mg for better efficacy
- Meta-analyses show a clear dose-response effect, with doses above 100 mg providing significantly greater preeclampsia risk reduction
- Aspirin should be initiated between 12-16 weeks of gestation for optimal benefit; starting after 16 weeks reduces effectiveness
- Risk stratification uses one high-risk factor (chronic hypertension, prior preeclampsia, diabetes, kidney disease) or two or more moderate risk factors
- The 2018 ACOG update added Black race, lower socioeconomic status, and IVF as moderate risk factors
- Some researchers advocate universal aspirin use in pregnancy regardless of risk factors due to low cost and low risk
- Data on aspirin for preterm birth prevention is accumulating but ACOG still considers this indication somewhat controversial
Key Moments
The Evolving Dosing Debate - 81 mg vs 150-162 mg
Dr. Chapa introduces the central question of whether 81 mg aspirin is sufficient for preeclampsia prevention or if higher doses of 150-162 mg are needed based on evolving evidence.
"Is 81 milligrams a day the current dose recommended in the U.S.?"
ACOG Risk Stratification for Aspirin in Pregnancy
Review of how ACOG has expanded its risk algorithm since 2013, adding Black race, lower socioeconomic status, and IVF as moderate risk factors in the 2018 and 2021 updates.
"We've got several things that we're going to talk about in this episode, including the last ACOG practice advisory, which was December 2021, that came off the heels of the U.S. Preventative Service Task Force expansion of criteria, basically expanding the moderate risk to include black race and lower socioeconomic status. All right. So those have been the recent releases from the college."
Meta-Analysis Evidence for Dose-Response Effect
Stephanie Roberge's 2017 meta-analysis of 45 randomized trials and nearly 20,000 participants demonstrated a dose-response relationship, with the greatest preeclampsia risk reduction seen above 100 mg.
"If you're ever asked, so what is more important, the dose of aspirin or when you start it? The answer is yes. Okay. Yes. Both the dose and the timing of initiation impact the effectiveness regarding preeclampsia prevention. They both have a role here. One of the biggest meta-analysis of RCTs that looked at this was in 2017."
